Clinical trials: Immune Development
Asthma, Perennial Allergic Rhinitis
Development of Cockroach Immunotherapy by the Inner-City Asthma Consortium
This trial is a biomarker-based pilot study of the safety of Cockroach Subcutaneous Immunotherapy in Cockroach-sensitive Adults (SCITCO) who have a history of perennial allergic rhinitis, asthma, or both.
- Trial name
- NCT01221285
- Testing
- German cockroach (Blattella germanica) allergenic extract
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Myeloma
Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma
This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-11 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.
- Trial name
- NCT03994705
- Testing
- Descartes-11, Fludarabine, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Cartesian Therapeutics
Leukemia
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy, such as clofarabine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00372619
- Testing
- clofarabine, cytarabine, methotrexate
- Where
- 79 sites in United States, Canada
- Volunteers
- 74 people
- Sponsor
- Children's Oncology Group
Multiple Myeloma
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of the study is to characterize safety of JNJ-68284528 and establish the recommended Phase 2 dose (RP2D) (Phase 1b) and to evaluate the efficacy of JNJ-68284528 (Phase 2).
- Trial name
- CARTITUDE-1 (NCT03548207)
- Testing
- JNJ-68284528
- Where
- 21 sites in United States, Japan
- Volunteers
- 126 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma
To assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse/ refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
- Trial name
- NCT03269136
- Testing
- PF-06863135 monotherapy IV or SC, PF-06863135 + dexamethasone, PF-06863135 + lenalidomide
- Where
- 37 sites in United States, Canada
- Volunteers
- 101 people
- Sponsor
- Pfizer
Human Immunodeficiency Virus
Development of Method of Fructose Identification in Urine to Detect the Viral Infection
The goal of this research is the attempt to implement a new research method based on modern electrochemistry successes, in particular the development of the polarographic method of fructose and fructose diphosphate identification…
- Trial name
- NCT01638312
- Where
- Taiwan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Relapsed or Refractory Multiple Myeloma
MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma
The purpose of this study is to confirm the safety and tolerability of elranatamab (PF-06863135) in Japanese participants with relapsed or refractory MM.
- Trial name
- NCT04798586
- Testing
- Elranatamab (PF-06863135)
- Where
- 2 sites in Japan
- Volunteers
- 4 people
- Sponsor
- Pfizer
Food Hypersensitivity, Milk Hypersensitivity
Study of Milk Allergy and Tolerance in Children
The purpose of this study is to determine if children who are allergic to milk can increase tolerance through frequent dose-escalation every 6 months versus 12 months leading to eventual tolerance of less heated milk and…
- Trial name
- NCT00778258
- Testing
- Baked Milk, Non-baked Milk
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Photoallergy
Evaluation of Potential Development of Photoallergic Skin Reaction After Use of MC2-01 Cream
This trial is a 6-week, Randomized study evaluating the potential of MC2-01 Cream to induce a photoallergic skin reaction in Healthy subjects, using a controlled photopatch test design.
- Trial name
- NCT03899064
- Testing
- Induction: Application of MC2-01 Cream, irradiation, Induction: Application of MC2-01 Cream, no irradiation, Induction: Applications of MC2-01 vehicle, irradiation
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- MC2 Therapeutics